Mark S. Gelder
2022 - Onconova Therapeutics
In 2022, Mark S. Gelder earned a total compensation of $677.6K as Chief Medical Officer at Onconova Therapeutics.
Compensation breakdown
| Bonus | $131,741 |
|---|---|
| Option Awards | $81,589 |
| Salary | $425,000 |
| Stock Awards | $31,850 |
| Other | $7,458 |
| Total | $677,638 |
Gelder received $425K in salary, accounting for 63% of the total pay in 2022.
Gelder also received $131.7K in bonus, $81.6K in option awards, $31.9K in stock awards and $7.5K in other compensation.
Rankings
In 2022, Mark S. Gelder's compensation ranked 3,766th out of 5,520 executives tracked by ExecPay. In other words, Gelder earned more than 31.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,766 out of 5,520 | 32nd |
Division Manufacturing | 2,120 out of 2,994 | 29th |
Major group Chemicals And Allied Products | 1,015 out of 1,344 | 25th |
Industry group Drugs | 951 out of 1,247 | 24th |
Industry Pharmaceutical Preparations | 693 out of 901 | 23rd |
Source: SEC filing on June 7, 2023.
Gelder's colleagues
We found two more compensation records of executives who worked with Mark S. Gelder at Onconova Therapeutics in 2022.